Acquistion of a ClonePix FL System

收购 ClonePix FL 系统

• 批准号: 7794638
• 负责人: ALBERT B REYNOLDS
• 金额: $ 46万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-02-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794638
• 关键词: Academic Medical Centers; Area; Biology; Cancer Center; Cell Line; Chemicals; Community Healthcare; Core Facility; Country; Detection; Diagnosis; Explosion; Funding; Hand; Health; Health Services Research; Housing; Hybridomas; Individual; Institutes; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Mass Spectrum Analysis; Mission; Monoclonal Antibodies; Mouse Models of Human Cancer Consortium; Process; Productivity; Proteomics; Reagent; Reproduction spores; Request for Applications; Research; Resource Sharing; Role; Screening procedure; System; Time; United States National Institutes of Health; Vaccines; Work; anticancer research; clinical application; instrument; meetings; programs; public health relevance; success; therapeutic target; tool

DESCRIPTION (provided by applicant): This application requests funds to purchase a dedicated ClonePix FL system (Genetix Ltd.) to automate the screening and selection of monoclonal antibody-secreting hybridoma cell lines. The instrument will be housed and operated by the Vanderbilt Monoclonal Antibody Core (VMAC) in support of several major Vanderbilt users, including the Vanderbilt-Ingram Cancer Center (VICC), Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt Vaccine Center, Special Program of Research Excellence in Gastrointestinal Cancer (GI- SPORE), Mouse Models of Human Cancer Consortium (MMHCC), Vanderbilt Institute of Chemical Biology (VICB), and a wide spectrum of research programs within the Vanderbilt University Medical Center (VUMC). The vast majority of these users are involved in cancer- or other health-related research efforts supported by NIH. Over the past ten years, Vanderbilt has built one of the finest Core Facility Networks in the country. Accelerated success in discovery areas such as proteomics, mass spectrometry, and targeted therapeutics (see Research Programs and Shared Resources in appendix) has generated an explosion in demand for new mAb's and significantly more activity than the VMAC can handle. The current backlog is almost three months and the projected demand for next year could extend delays to over six months. The main bottleneck is the labor-intensive task of generating and screening hybridoma cell lines to identify desired clones. The ClonePix system dramatically increases productivity by automating most aspects of this process. Last year, the VMAC topped out at 28 fusions with two technicians working significant overtime. The ClonePix system will enable these individuals to perform as many as ~100 fusions/year while reducing hands on time. PUBLIC HEALTH RELEVANCE: Monoclonal antibodies are critically important tools in a broad range of research and clinical applications used to study and treat cancer. A key role of the VMAC is to accelerate progress in multiple areas of health and cancer research by making these crucial reagents inexpensive, easy to make, and readily available to the Vanderbilt research and healthcare community. The instrument described in this application is central to this mission and essential for the VMAC's ability to meet Vanderbilt demand for these critical research tools.

描述（由申请人提供）：此申请要求资金购买专用的ClonePix FL系统（Genetix Ltd.），以自动化单克隆抗体分泌杂交瘤细胞系的筛选和选择。该乐器将由范德比尔特单克隆抗体核心（VMAC）托管和运营，以支持几位主要的范德比尔特用户，包括范德比尔特 - 伊格兰癌症中心（VICC），吉姆·艾尔斯（Jim Ayers），吉姆·艾尔斯（Jim Ayers胃肠道癌（Gi-Spore），人类癌症联盟的小鼠模型（MMHCC），范德比尔特化学生物学研究所（VICB）（VICB）以及范德比尔特大学医学中心（VUMC）内的广泛研究计划的研究卓越。这些用户中的绝大多数参与了NIH支持的癌症或其他与健康有关的研究工作。在过去的十年中，范德比尔特（Vanderbilt）建立了该国最好的核心设施网络之一。在蛋白质组学，质谱和有针对性的治疗学等发现领域的成功（请参阅附录中的研究计划和共享资源）加速了成功，这对新MAB的需求产生了爆炸，并且比VMAC可以处理的活动要多得多。当前的积压待定将近三个月，预计明年的需求可能会将延迟延长到六个月以上。主要的瓶颈是产生和筛选杂交瘤细胞系以识别所需克隆的任务。 ClonePix系统通过自动化此过程的大多数方面来大大提高生产率。去年，VMAC与两名技术人员的加时赛大量融合了28个融合。 ClonePix系统将使这些人能够每年进行多达〜100个融合，同时及时减少手。 公共卫生相关性：在用于研究和治疗癌症的广泛研究和临床应用中，单克隆抗体是至关重要的工具。 VMAC的关键作用是通过使这些关键的试剂廉价，易于制造，并且很容易为范德比尔特研究和医疗保健社区提供，以加快健康和癌症研究的进步。本应用程序中描述的工具对于此任务至关重要，对于VMAC满足范德比尔特对这些关键研究工具的需求的能力至关重要。